Avenue Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2018

Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]

The following table sets forth the common shares that could potentially dilute basic income per share in the future that were not included in the computation of diluted income (loss) per share because to do so would have been anti-dilutive for the periods presented:

	For the Three and Six Months Ended
	June 30,		June 30,
	2018		2017
Restricted stock units/awards		673,332		199,999
Preferred shares		250,000		250,000
Options		20,000		-
Total potential dilutive effect		943,332		449,999